Compare Globus Medical Inc. Class A Common Stock (GMED) vs Direxion Daily FTSE China Bull 3x Shares (YINN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Direxion Daily FTSE China Bull 3x Shares — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Direxion Daily FTSE China Bull 3x Shares trades at $24.12 (market cap $600.54M). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 17.1× Direxion Daily FTSE China Bull 3x Shares's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Direxion Daily FTSE China Bull 3x Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Direxion Daily FTSE China Bull 3x Shares for 26 Days on average.
| GMED | YINN | |
|---|---|---|
Market Cap | $10.25B | $600.54M |
Volume | 1,108,124 | 729,546 |
Sector | Health | Leveraged / Inverse |
52-Week High | $96.82 | $52.69 |
52-Week Low | $58.33 | $21.45 |
Typical Hold Time | 0 Days | 26 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
YINN trades at $25.06, up 0.36% with bearish technical signals from moving averages. The stock shows neutral momentum oscillators with RSI at 44.85. Recent news highlights China's economic policies affecting Asian markets, though YINN's specific financial metrics remain undisclosed in current data. The stock faces concentrated support/resistance around $25.
Outlook remains cautious with technical indicators suggesting bearish pressure. Investment opportunity depends on China's economic recovery and policy developments. Key risks include regulatory changes and market volatility. Analyst consensus and institutional positioning data are currently unavailable for assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Direxion Daily FTSE China Bull 3x Shares
YINN is a leveraged ETF that seeks daily investment results, before fees and expenses, of 300% (3x) of the daily performance of the FTSE China 50 Index. It is a tactical instrument designed for sophisticated traders seeking to magnify short-term bullish views on large-cap Chinese equities, primarily those trading on the Hong Kong Stock Exchange.
Read more on YINN →
